Bivalirudin vs Ipamorelin
Overview
Bivalirudin is primarily a cardiovascular peptide, while Ipamorelin is used for performance & growth.
This page compares Bivalirudin and Ipamorelin across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Bivalirudin | Ipamorelin | |
|---|---|---|
| Category | Cardiovascular | Performance & Growth |
| Regulatory status (US) | FDA approved | Research use only |
| Typical dosage | 0.75 mg/kg IV bolus, then 1.75 mg/kg/h IV infusion | 200-300 mcg |
| Frequency | Single procedural session: bolus immediately before PCI followed by continuous infusion during the procedure; optional post-procedural infusion for up to approximately 20 hours | twice-daily |
| Reported benefits | Anticoagulation during PCI and PTCA, anticoagulation in HIT/HITTS patients undergoing PCI, reduced major bleeding versus heparin plus glycoprotein IIb/IIIa inhibitor, predictable pharmacokinetics without need for antithrombin cofactor, rapid offset of anticoagulation due to short half-life, inhibition of both circulating and clot-bound thrombin | Natural GH release, improved body composition, better sleep, anti-aging effects, no appetite increase |
| Reported side effects | Bleeding (most common, including access-site and retroperitoneal), acute stent thrombosis (early, within 24 hours), back pain, nausea, headache, hypotension, injection-site pain, hypersensitivity reactions, thrombocytopenia (rare) | Very well-tolerated. Rare: headache, injection site reactions |
Key differences
Primary use. Bivalirudin is categorised under Cardiovascular, while Ipamorelin falls under Performance & Growth. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.
Regulatory status. Bivalirudin: FDA-approved. Ipamorelin: not FDA-approved; treated as a research compound.
Dosing. Bivalirudin is typically dosed at 0.75 mg/kg IV bolus, then 1.75 mg/kg/h IV infusion (Single procedural session: bolus immediately before PCI followed by continuous infusion during the procedure; optional post-procedural infusion for up to approximately 20 hours). Ipamorelin is typically dosed at 200-300 mcg (twice-daily).
Can you stack them?
Some protocols combine peptides, but stacking Bivalirudin and Ipamorelin has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Bivalirudin and Ipamorelin?
- Bivalirudin is primarily a cardiovascular peptide, while Ipamorelin is used for performance & growth. Bivalirudin is FDA-approved for one or more indications, whereas Ipamorelin is not FDA-approved; generally classified as a research compound.
- What is Bivalirudin used for?
- FDA-approved synthetic peptide direct thrombin inhibitor used for anticoagulation during PCI, including in HIT patients.
- What is Ipamorelin used for?
- GH secretagogue, anti-aging.
- Can you take Bivalirudin and Ipamorelin together?
- Some users combine peptides within a single protocol, but stacking Bivalirudin and Ipamorelin has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Bivalirudin or Ipamorelin FDA-approved?
- Bivalirudin is FDA-approved for one or more indications. Ipamorelin is not FDA-approved; generally classified as a research compound.
Read the full articles
- Bivalirudin — full monograph: mechanism, research, dosing & references
- Ipamorelin — full monograph: mechanism, research, dosing & references